Joseph Pandolfino,
Chief Executive Officer

Founder of Cabbacis, Joe is the inventor on the company’s patents and leads the strategic direction of Cabbacis. He is also the founder, and was the first CEO, of 22nd Century Group, Inc. (Nasdaq: XXII) and led the process of 22nd Century becoming publicly traded in 2011. Under his leadership, the company up-listed to the New York Stock Exchange in 2013 and achieved a market capitalization of $373 million in 2014. Joe rang the Closing Bell at the New York Stock Exchange on October 16, 2014. He left 22nd Century as CEO later in 2014 and as a director in 2015. Joe’s previous company funded the R&D project of reducing nicotine in tobacco by genetic engineering that resulted in the lowest-nicotine-content tobacco variety ever commercialized. A plant variety protection (PVP) certificate was granted from the USDA for this tobacco variety, and the technology, variety rights, and related patent rights were spun out by Joe to a newly formed company, 22nd Century Limited. He has more than 25 years’ experience in all aspects of the tobacco industry, including product development and marketing, and has more than 10 years’ experience in both plant biotechnology and cannabis. He holds an MBA from the University at Buffalo.

Michael R. Moynihan, PhD,
Vice President of Research & Development

Mike has more than 30 years’ experience in all aspects of plant biotechnology, ranging from molecular genetics to development of novel consumer products. He led R&D efforts at 22nd Century Group for 11 years, during which he played a major role in the development and production of Nicotine Research Cigarettes with different nicotine contents for the National Institute on Drug Abuse (NIDA). The Nicotine Research Cigarette series included cigarettes with nicotine concentrations ranging from higher than average to less than 5% of typical commercial cigarettes. Data from studies using these cigarettes, much of it funded by the National Institutes of Health and the Center for Tobacco Products of the Food and Drug Administration, provided the foundation for the authorization for sale of a very low nicotine cigarette brand as a Modified Risk Tobacco Product (MRTP) in the United States. Mike’s other professional experience includes serving as Director of Biotechnology Development at Fundación Chile, Senior Project Director at InterLink Biotechnologies LLC, Principal Scientist, Cell Biology at EniChem Americas Inc., Visiting Research Fellow at the Institute for Molecular and Cellular Biology, Osaka University, Postdoctoral Associate in the Section of Plant Biology, Cornell University, and Postdoctoral Associate at the Center for Agricultural Molecular Biology, Rutgers University. Dr. Moynihan holds an ScB in Biology from Brown University and an MA and PhD in Biology from Harvard University. 

John C. Manley, Jr., CPA,
Chief Financial Officer

Entrepreneurial CPA, business coach, and strategist whose “highest and best” use is managing businesses. Jack has over 30 years’ experience establishing, managing, restructuring, and selling privately held businesses. Extensive experience as a business leader in the health care, real estate, professional services, mortgage banking, distribution, and logistics industries. Founded U.S. Appraisal and serving as CEO, launched this regional real estate valuation services company into a national mortgage-industry leader. Led acquisition team in acquiring a large regional distribution company and completely redeveloped its infrastructure over a three-year period. Jack is committed to operational fundamentals and controls, with Big Four auditing experience at Deloitte. He holds a BS from Niagara University and is a Certified Public Accountant, licensed by the New York State Education Department.